Radioisotope (e.g., Radioimmunoassay, Etc.) Patents (Class 436/804)
-
Patent number: 5082928Abstract: The present invention is directed to a method of preparing a conjugated antibody agent, and conjugated antibody agent obtained thereby. The method includes:(i) attaching a substantially pure antigen to a solid phase;(ii) passing an antibody containing composition over the solid phase such that the antibody is caused to bind to the attached antigen by immunoreaction to form a bound antigen-antibody complex;(iii) passing a reactive conjugating agent over the bound antigen-antibody complex to conjugate the conjugating agent to said complex; to(iv) removing the resultant conjugated antibody from the solid phase.Type: GrantFiled: November 13, 1989Date of Patent: January 21, 1992Inventor: Mark P. Best
-
Patent number: 5071963Abstract: Human DNA encoding enzymes having (2'-5') oligo A synthetase has been sequenced. The amino acid sequences of the enzymes have been deduced. Antigenic peptides have been prepared and have been used to raise antibodies which recognize and immunoprecipitate the 40 kd, 46 kd, 67 kd and 100 kd forms of (2'-5') oligo A synthetase. Methods of monitoring interferon activity in a subject are presented.Type: GrantFiled: April 8, 1987Date of Patent: December 10, 1991Assignee: Yeda Research and Developement Co., Ltd.Inventors: Michel Revel, Judith Chebath
-
Patent number: 5061641Abstract: A protein containing at least one pendant sulfhydryl group is directly radiolabeled with a radiometal which binds tightly to sulfhydryl groups, using one or more pendant sulfhydral groups on the protein as endogenous ligands and optionally using an exogenous ligand which binds tightly to the radiometal ion to further stabilize the chelate.Type: GrantFiled: April 1, 1988Date of Patent: October 29, 1991Assignee: Immunomedics, Inc.Inventors: Dan Shochat, Hans J. Hansen, Robert S. Wu
-
Patent number: 5059541Abstract: There is disclosed a process for minimally derivatizing a targeting protein with a radionuclide such that the predominant species of derivatized targeting protein contains one radionuclide group as a single radiolabeled ligand, and whereby the binding characteristics of the targeting protein are minimally affected. There is further disclosed ligands that can chelate a metal radionuclide or bind a halogen radionuclide while providing a means for separating radiolabeled ligand from unradiolabeled ligand.Type: GrantFiled: April 29, 1988Date of Patent: October 22, 1991Assignee: Neorx CorporationInventors: Alan R. Fritzberg, Daniel S. Wilbur, Ananthachari Srinivasan, Dennis W. Wester
-
Patent number: 5053493Abstract: A simple, rapid and efficient method for labelling sulfhydryl-containing antibodies or antibody fragments with Tc-99m, Rh-186, Rh-188, Rh-189 or Rh-191 is disclosed. Labeled antibodies produced by the method are useful for radio-immunodiagnostic and/or radio-therapeutic purposes.Type: GrantFiled: April 2, 1987Date of Patent: October 1, 1991Assignee: Centocor Cardiovascular Imaging Partners, L.P.Inventors: Koon Y. Pak, Richard T. Dean, Jeffrey A. Mattis
-
Patent number: 5041389Abstract: Improved asssays are provided for anti-acetylcholine receptor protein autoantibodies in the sera of patients with myasthenia gravis. The basis for the improved assays is the discovery that large quantities of acetylcholine receptor protein, that, for practical purposes in immunoassays, is immunologically indistinguishable from human muscle acetylcholine receptor protein, can be isolated from cells of the human medullablastoma-derived cell line TE671.Type: GrantFiled: May 29, 1990Date of Patent: August 20, 1991Assignee: The Salk Institute for Biological StudiesInventor: Jon M. Lindstrom
-
Patent number: 5041390Abstract: The histamine in a sample is determined by contacting the sample with a histamine binding agent, such as glass, which has been treated, e.g., with a polar organic polymer, to reduce the affinity of the agent for an interfering component of the sample while substantially retaining the agent's histamine binding capacity. Such an agent facilitates determination of histamine in whole blood samples. Preferably, the agent is provided as a conglomerate of histamine-binding bodies, such as glass fibers, in a binder. Preferred binders are polyvinyl acetate, a vinyl acetate/ethylene copolymer, and polyvinyl alcohol or combinations thereof.Type: GrantFiled: October 17, 1988Date of Patent: August 20, 1991Inventors: Per S. Skov, Ole-Christian Bjarno
-
Patent number: 5024828Abstract: Novel isomers or mixtures of isomers of radioactive pyrethrinoids marked with iodine of the formula ##STR1## wherein X.sub.1 is selected from the group consisting of halogen and --CF.sub.3, X.sub.2 is a halogen, R is the residue of an amino acid of the formula R--NH.sub.2 or a derivative thereof containing an iodine acceptor group and marked with iodine.sup.125 or iodine.sup.131, process for their preparation and intermediates and their use in radioimmunological determination.Type: GrantFiled: January 28, 1987Date of Patent: June 18, 1991Assignee: Roussel UclafInventors: Jean-Pierre Demoute, Gaetan Touyer, Michel Mouren
-
Patent number: 5011771Abstract: The invention relates to an immunometric assay for a multivalent antigen in a sample which comprises forming a complex of the antigen together with multiple immobilized monoclonal antibodies against different epitopes of the antigen and with a detectably labeled soluble monoclonal antibody which is identical to one of the multiple immobilized antibodies. The labeled antibody associated with the complex is separated from the remaining soluble antibody and the detectably labeled antibody associated with the complex or unassociated with the complex is detected. Any one of the multiple immobilized monoclonal antibodies shows, by itself, substantially less binding towards the antigen in the immunometric assay, when used with itself or another monocolonal antibody in soluble labeled form, than when used with the multiple immobilized antibodies in combination.Type: GrantFiled: September 24, 1987Date of Patent: April 30, 1991Assignee: The General Hospital CorporationInventors: Dominique Bellet, Jack R. Wands
-
Patent number: 5011781Abstract: Disclosed is an improved autoradiography enhancer composition and method of use. The enhancer composition uses an acid anhydride as a dehydration agent.Type: GrantFiled: July 31, 1989Date of Patent: April 30, 1991Assignee: Electron Microscope Supplies CorporationInventor: Coleman Bess
-
Patent number: 5001072Abstract: Compositions and methods are disclosed for multiple simultaneous assays of different analytes using radioactive labeled antibodies to the analytes, at least one portion of the assay being an immunoradiometric assay in which there is employed a metal isotope label, e.g., .sup.57 Co, attached to an antibody to the analyte through a chelator, e.g., ethylenediaminetetraacetic acid. Multiple simultaneous immunoradiometric assays can be performed by this method, as can multiple simultaneous assays in which one portion of the assay is an immunoradiometric assay and another portion or portions involve one or more other radioassay techniques.Type: GrantFiled: June 8, 1987Date of Patent: March 19, 1991Assignee: ICN Biomedicals Inc.Inventor: Douglas R. Olson
-
Patent number: 4997771Abstract: The invention describes a method for determining the BZ-1 receptor activity of a test sample or a potential anxiolytic drug.Type: GrantFiled: April 27, 1987Date of Patent: March 5, 1991Assignee: Schering CorporationInventors: Allen Barnett, William Billard, Gordon Crosby, Jr., Louis Iorio, Martin Steinman
-
Patent number: 4992366Abstract: A receptor preparation of biologically active receptor material is produced in which a cell membrane preparation is lyophilized accompanied by the addition of sugars and/or amino acids and/or proteins. A radioreceptor assay can be produced therefrom, which contains the colyophilizate of cell membrane together with sugar compounds and/or amino acids and/or proteins, as well as a tracer substance and a comparison standard substance. A radioreceptor assay kit uses the radioreceptor assay by making available the substances in a plurality of test containers containing a colyophilizate suitable for the assay.Type: GrantFiled: June 10, 1988Date of Patent: February 12, 1991Assignee: Anawa Laboratorien AGInventor: Ernst Buergisser
-
Patent number: 4966856Abstract: An analytical element and method using the element for measuring a specific component in a fluid sample such as blood, serum, plasma, urine, sweat etc. The fluid sample is applied on the element with a labeled-material formed by binding the specific component or the analogue of it with a labeling material causing a signal. The element comprises a reaction layer and an absorption layer. The reaction layer contains a material which is capable of specifically binding with the component to be measured and the absorption layer contains a material which capable of binding with the labeled material and decreasing a signal caused by the labeling material. A strength of the signal caused labeled-material in the reaction layer is determined to measure the specific component.Type: GrantFiled: October 15, 1987Date of Patent: October 30, 1990Assignee: Konishiroku Photo Industry Co., Ltd.Inventors: Tsukasa Ito, Satoshi Kawakatsu, Akira Onishi, Masayo Takekoshi
-
Patent number: 4962023Abstract: An immunoassay method for one-step detection of specific antibodies which includes incubation of a solid phase support or matrix having a spot of the antigen bound thereto with a sample of the clinical fluid to be tested in the presence of a signal developing reagent, including a detector substance, which is preferably a colloidal metal sol, and a ligand, such as protein A or other antibody binding ligand. A diagnostic field kit containing the test antigens and signal developing reagent is also described.Type: GrantFiled: June 22, 1987Date of Patent: October 9, 1990Assignee: Louisiana State University, Agricultural and Mechanical CollegeInventors: William J. Todd, Paul A. Barstad
-
Patent number: 4954434Abstract: The present invention relates to a method of diagnosis of pathological pregnancy which relies on an evaluation of the amount of placental isoferritin (PLF) in the serum or amniotic fluid of a pregnant woman. Diagnosis may also be achieved by observation of percentages of PLF-bearing lymphocytes in the pregnant female. Detection of PLF levels is achieved by immunoassay with a PLF-specific anitbody. Also described is a method of treating or preventing pathological pregnancies and transplant or graft rejection by administration of effective amounts of PLF and/or a PLF-specific antibody in combination with immunization.Type: GrantFiled: June 23, 1988Date of Patent: September 4, 1990Inventor: Chaya Moroz
-
Patent number: 4943523Abstract: A detectable molecule of the formulaA.sup.3 --(--X--R.sup.1 --E--Det.sup.b).sub.mwhere A.sup.3 is A.sup.2 or a polymer, where A.sup.3 has at least one modifiable reactive group selected from the group consisting of amino, hydroxy, cis OH, halides, aryl, imidazoyl, carbonyl, carboxy, thiol or a residue comprising an activated carbon; --X-- is selected from the group consisting of ##STR1## a C.sub.1 -C.sub.10 branched or unbranched alkyl or aralkyl, which may be substituted by --OH; --Y-- is a direct bond to --E--, or --Y-- is --E--R.sup.2 -- where R is a C.sub.1 -C.sub.10 branched or unbranched alkyl; Z.sub.a is chlorine, bromine or iodine; E is O, NH or an acyclic divalent sulfur atom; Det.sup.b is a chemical moiety capable of being detected, preferably comprising biotin or a metal chelator of the formula: ##STR2## or the 4-hydroxy or acyloxy derivative thereof, where R.sup.3 is C.sub.1 -C.sub.4 alkyl or CH.sub.Type: GrantFiled: April 28, 1987Date of Patent: July 24, 1990Assignee: Enzo Biochem, Inc.Inventor: Jannis G. Stavrianopoulos
-
Patent number: 4929544Abstract: Human cancer is diagnosed/monitored by measuring the levels of N-[9-(.beta.-D-ribofuranosyl)purin-6-ylcarbamoyl]-L-threonine (t.sup.6 A), in a physiological fluid specimen of a subject by a quantitative immunoassay that employs a monoclonal anti-t.sup.6 A antibody and comparing that level to the level of t.sup.6 A that occurs in corresponding physiological fluid of normal subjects to determine whether the former is substantially elevated over the latter or by comparing that level to the level of t.sup.6 A present in specimens taken from the subject at different times.Type: GrantFiled: August 27, 1986Date of Patent: May 29, 1990Assignee: SRI InternationalInventor: Barbara S. Vold
-
Patent number: 4921808Abstract: The present disclosure relates to an improved method based on hormone-receptor binding for the determination of follicle stimulating hormone and to improved reagents useful for the determination of follicle stimulating hormone in a hormone-receptor binding assay.Type: GrantFiled: June 25, 1986Date of Patent: May 1, 1990Assignee: The Albany Medical College of Union UniversityInventors: Alan L. Schneyer, Patrick M. Sluss, Bosukonda Dattatreyamurty, Leo E. Reichert, Jr.
-
Patent number: 4912030Abstract: Samples e.g. transfusion blood, are assayed for antibodies to retroviruses, e.g. AIDS virus, using an insolubilized antigen comprising retrovirus antigens bound to globulin, the globulin itself being bound to an inert solid support; and an immunoglobulin which contains specific antibody to the retrovirus antigens and which is labelled with a revealing label, and the soluble phase is then separated from the insoluble phase and the quantity of revealing label associated with either the soluble or the insoluble phase determined.The sue of labelled antibody in competition with test sera for binding on the insolublized antigen permits better identification of antibody containing specimens. The retroviruses may be a human T-lymphotropic retrovirus HTLV-I, II or III or a new retrovirus isolate CBL-1 etiologically related to AIDS.Type: GrantFiled: April 5, 1988Date of Patent: March 27, 1990Assignee: Institute of Cancer ResearchInventors: Robin Weiss, Richard Tedder, Rachanee Cheingsong-Popov, Bridget Ferns
-
Patent number: 4912031Abstract: A method for distinguishing between carcinomatous and/or precarcinomatous colo-rectal disease and histologically similar conditions due to diseases that are not carcinomatous or precarcinomatous comprising contacting colo-rectal tissue with an antibody that binds to blood group substance H and determining the presence of carcinomatous or precarcinomatous disease upon a finding of bound antibody, or the absence of such disease upon the finding of no bound antibody.Type: GrantFiled: October 23, 1987Date of Patent: March 27, 1990Assignee: E. I. Du Pont de Nemours and CompanyInventors: Carolyn C. Compton, Paul J. Durda
-
Patent number: 4910152Abstract: A method of controlling weight in a mammal and diagnosing, treating, and preventing disorders associated with delta-type opioid receptors comprising administering to the mammal a receptor probe or a weight control agent for inhibiting weight gain. The receptor probe or weight control agent may comprise certain azine, thiosemicarbazone, or N,N'-disubstituted thiourea derivatives of nonpeptide opioid antagonists.Type: GrantFiled: June 2, 1986Date of Patent: March 20, 1990Inventors: Vera K. Meyers, Ahmet Koman
-
Patent number: 4879219Abstract: Hybridomally produced monoclonal IgM antibodies having high affinity are useful for the immunoassay and purification of viral antigens.Type: GrantFiled: September 19, 1980Date of Patent: November 7, 1989Assignee: General Hospital CorporationInventors: Jack R. Wands, Vincent R. Zurawski, Jr., Schoemaker, Hubert J. P.
-
Patent number: 4879216Abstract: The present invention provides a specific antibody against heart muscle light chains (HMLC) with a cross-reactivity against skeletal muscle light chains (SMLC) of less than 5%. The present invention also provides a process for the preparation of this specific antibody, wherein a mammal is immunized with HMLC I and/or HMLC II and the crude serum is recovered and subjected to an immunosorptive purification on an SMLC immune adsorbent based on silicate. Furthermore, the present invention provides a reagent for the determination of HMLC which contains antibodies against HMLC according to the present invention.Type: GrantFiled: March 8, 1988Date of Patent: November 7, 1989Assignee: Boehringer Mannheim GMBHInventors: Klaus Hallermayer, Siegfrid Looser, Hugo Katus
-
Patent number: 4877746Abstract: Method for carrying out immunochemical assays for lipoproteins and/or apolipoproteins, wherein prior to the reaction of the sample with the appropriate anti(apolipoprotein) or anti(lipoprotein) antibody the pH of the sample is maintained at a non-denaturing value in a pretreatment step for exposing antigenic determinants, said non-denaturing value lying above pH 9.0 or below pH 3.0. After the pre-treatment step the pH is adjusted for immune reaction, so that then the immunochemical assay can be carried out in a manner known per se.Type: GrantFiled: April 21, 1987Date of Patent: October 31, 1989Assignee: Pharmacia ABInventors: Gunnel B. Jansson, Erling S. Holmlund
-
Patent number: 4873188Abstract: The present invention is concerned with two novel monoclonal antibodies which define carbohydrate antigens associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. The invention also comprises a method for determining the presence of a malignant condition in the lung of a subject. The method involves examining tissue from the subject for the presence of antigens which are Le.sup.x or Le.sup.y antigen or which have the characteristics of Le.sup.y and Le.sup.x.Type: GrantFiled: May 28, 1985Date of Patent: October 10, 1989Assignee: OncogenInventors: Ingegerd Hellstrom, Joseph P. Brown, Karl E. Hellstrom, Diane Horn, Peter Linsley
-
Patent number: 4863850Abstract: A substantially pure rheumatoid arthritis specific protein (RASP) and an antibody against the rheumatoid arthritis specific protein (anti-RASP antibody) are disclosed. The RASP is found specifically in the serum or plasma of a patient suffering from rheumatoid arthritis, and may be detected using an anti-RASP antibody easily and effectively. Therefore, the anti-RASP antibody of the present invention is useful for the diagnosis of rheumatoid arthritis by the criterion of the presence of RASP.Type: GrantFiled: February 16, 1988Date of Patent: September 5, 1989Assignees: Asahi Medical Co., Ltd, Medecs Co., Ltd.Inventors: Naoki Yamanaka, Makoto Yoshida
-
Patent number: 4855227Abstract: A clinical diagnostic method capable of rapidly detecting the presence of Mycoplasma pneumoniae in infected humans is taught. The method allows a proper course of therapy to be chosen within one day of presentation of the patient.Type: GrantFiled: June 7, 1985Date of Patent: August 8, 1989Assignee: Institute for Medical ResearchInventors: Gerard J. McGarrity, Hitoshi Kotani
-
Patent number: 4855241Abstract: An in vitro diagnostic method for determining the presence of nerve growth factor receptor bearing tumors is disclosed which comprises determining the presence of an elevated level of a truncated nerve growth factor receptor in a sample of a body fluid from a patient afflicted with such tumor.Type: GrantFiled: May 26, 1988Date of Patent: August 8, 1989Assignee: Washington UniversityInventor: Eugene M. Johnson, Jr.
-
Patent number: 4855242Abstract: A method for determining the quantity of an antibody in a sample, the method having the steps of: (1) providing a labelled antigen to the antibody; (2) contacting the labelled antigen with the sample in solution to form a labelled antigen-antibody complex; (3) providing an agent for precipitating the complex; (4) mixing the solution containing the labelled antigen-antibody complex with the precipitating agent to produce a precipitate and a supernatant; the supernatant containing labelled antigen and the precipitate containing the labelled antigen-antibody complex and uncomplexed labelled antigen; and (5) measuring the quantity of label in the precipitate or the supernatant in a manner substantially independent of the amount of uncomplexed labelled antigen in the precipitate.Type: GrantFiled: January 6, 1987Date of Patent: August 8, 1989Assignee: Joslin Diabetes Center, Inc.Inventor: J. Stuart Soeldner
-
Patent number: 4851356Abstract: An immunoassay for detecting and measuring hCG in a sample includes an antibody directed to the carboxy terminal portion of the .beta. subunit of hCG and a monoclonal antibody directed to a determinant on hCG at a locus sufficiently remote from the carboxy terminal portion of the .beta. subunit of hCG that both antibodies can simultaneously bind to hCG, wherein at least one of the antibodies is delectable when both are bound to hCG.In a presently preferred embodiment, an immunoassay for hCG or hCB.beta. in urine includes a purified, labeled or detectable serum-derived antibody directed to the carboxy-terminal portion of the .beta. subunit of hCG and a matrix-bound monoclonal antibody directed to a locus on the .beta. subunit sufficiently remote from the carboxy-terminal portion that both antibodies can simultaneously bind to hCG or hCG.beta..Type: GrantFiled: July 14, 1987Date of Patent: July 25, 1989Assignee: The Trustees of Columbia University in the City of New YorkInventors: Robert E. Canfield, Elmo G. Armstrong, Paul H. Ehrlich, Steven Birken
-
Patent number: 4845039Abstract: Method for labelling amine-containing compounds like proteins with a metal, particularly technetium-99m comprising reacting metal ions in an acidic medium with a compound represented by formulae (I) or (II), wherein R.sub.1, R.sub.2 and R.sub.3 are independently selected from hydrogen, alkyl, substituted alkyl, aryl, alkanyl etc. to form a reactive intermediate compound and thereafter reacting said reactive intermediate compound with the amine-containing compound to be labeled. This kind of labeled amine-containing compounds have beneficial properties in immuno-diagnostic and therapeutic applications, particularly when they are used in vivo.Type: GrantFiled: July 10, 1986Date of Patent: July 4, 1989Assignee: Academisch Ziekenhuis LeidenInventors: Ernest K. J. Pauwels, Rolf I. J. Feitsma
-
Patent number: 4843020Abstract: An improved method for the detection of tetrahydrocannabinol in human urine wherein the pigment melanin is precipitated out of the urine prior to analysis with a solution of nitroferricyanide so that the melanin does not interfere with the analysis. The value attributable to melanin can also be subtracted from the value obtained during the analysis of the urine. The precipitation of melanin prior to analysis or subtraction of the melanin value during analysis greatly reduces the occurrence of false positive test results for persons with dark skin.Type: GrantFiled: January 14, 1988Date of Patent: June 27, 1989Inventor: W. James Woodford
-
Patent number: 4843019Abstract: The invention relates to acino-fetal differentiation proteins associated with cancer of the pancreas, these proteins being mannoside-containing glycoproteins of average apparent molecular mass chosen from: 120 KD, 94 KD and 58 KD.The invention also relates to a method for preparing these proteins, an antiserum against these proteins and the method for preparation thereof, monoclonal antibodies against these proteins and the method for preparation thereof, and compositions for diagnostic or therapeutic use containing these proteins or antibodies.Type: GrantFiled: May 29, 1986Date of Patent: June 27, 1989Assignee: Centre National de la Recherche ScientifiqueInventors: Maria J. Escribano-Crespo, Pierre Burtin
-
Patent number: 4840895Abstract: A secondary monoclonal antibody against a complex of a molecule of molecular weight less than 5000 and a binding protein against said molecule which secondary monoclonal antibody is not an antibody against molecule or against its binding protein.Type: GrantFiled: November 18, 1985Date of Patent: June 20, 1989Assignee: Cambridge Patent Development LimitedInventor: Colin H. Self
-
Patent number: 4840894Abstract: A method for detecting the presence in a human of an integral membrane calcium-binding protein associated with essential hypertension which comprises isolating tissue from a human, treating the tissue to obtain integral membrane proteins, contacting the proteins thus obtained with a first antibody molecule which binds to the integral membrane calcium binding protein to form an detectable protein-antibody complex, and detecting the complex so formed.Further, methods for quantitatively determining the amount of an integral membrane calcium-binding protein and the messenger RNA encoding said protein, diagnostic methods for identifying individuals predisposed to essential hypertension, and protein and messenger RNA associated with said hypertension.Type: GrantFiled: March 4, 1986Date of Patent: June 20, 1989Assignee: The Trustees of Columbia University in the City of New YorkInventors: David Schachter, Szloma Kowarski, Lisa A. Cowen, Richard E. Abbott
-
Patent number: 4839299Abstract: A biological sample containing an analyte, partly free and partly bound to natural binders, is incubated with a labelled specific binder for the analyte and a derivative of the analyte which does not react with the natural binders. Part of the labelled specific binder binds to the analyte derivative, the proportion depending on the free analyte concentration in the sample. The proportion is measured and used to determine the free analyte concentration. For example, the analyte may be thyroxine or cortisol, the labelled specific binder may be an antibody thereto, and the analyte derivative may be in the form of a solid matrix. The labelled specific binder should have an affinity for the analyte, expressed as a dissociation constant of the complex of the two, approximately equal to the concentration of free analyte in the sample.Type: GrantFiled: July 17, 1987Date of Patent: June 13, 1989Assignee: Amersham International plc.Inventors: John C. Charlton, John E. Midgley, Terence A. Wilkins
-
Patent number: 4837167Abstract: A simultaneous sandwich immunoassay employing high-affinity monoclonal antibodies is disclosed. This simultaneous sandwich assembly has surprising sensitivity compared to forward and reverse sandwich assays for the detection of multi-determinant antigens such as hepatitis B surface antigen.Type: GrantFiled: April 24, 1984Date of Patent: June 6, 1989Assignees: Centocor, Inc., The General Hospital Corporation, Centocor, Inc.Inventors: Hubert J. P. Schoemaker, Jack R. Wands, Barbara L. Westrick, Vincent R. Zurawski, Jr.
-
Patent number: 4837003Abstract: Methods and reagents for attaching radionuclide metal ions to antibody fragments are disclosed. A coupling agent is employed which contains a maleimidyl group linked, through a divalent organic moiety, to a group capable of forming a chelate complex with the radionuclide metal ion. Antibody fragments labeled with radionuclide metal ions by the disclosed procedure are useful for in vivo diagnostic or therapeutic applications.Type: GrantFiled: September 13, 1984Date of Patent: June 6, 1989Assignee: Mallinckrodt, Inc.Inventor: Robert A. Nicolotti
-
Patent number: 4833073Abstract: Novel cannabinol derivatives are provided which can be used in improved immunoassays for the detection in blood or urine samples of cannabinol metabolites.Type: GrantFiled: January 27, 1987Date of Patent: May 23, 1989Assignee: Hoffmann-La Roche Inc.Inventors: Alan J. McNally, Alan Schwartz, Magdalena Usategui
-
Patent number: 4816417Abstract: An assay for 1,25-dihydroxy vitamin D is disclosed. One aspect of the invention involves adding pig receptor protein, radiolabeled, 1,25-dihydroxy vitamin D and biotinylated antibody capable of binding to the receptor to untreated blood serum. In performing a competitive binding assay, vitamin D transport protein, DBP, acts as a screen to minimize interference from related metabolites. A kit and an assay are disclosed.Type: GrantFiled: August 14, 1987Date of Patent: March 28, 1989Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Margaret C. Dame, Eric A. Pierce
-
Patent number: 4806492Abstract: Novel polypeptides, polynucleotide sequences, DNA constructs and compositions are provided for the preparation and use of polypeptides associated with naturally occurring polypeptides found in brains. The small molecular weight polypeptides are growth inhibitors for neoplastic cells without inhibiting normal cells. The polypeptides comprise specific regions which are highly conserved, separated by less conserved regions. The polypeptides find use in inhibiting neoplastic growth and detecting receptors for the polypeptides. Antibodies are provided in conjunction with the polypeptides, which may be used together or separately for detecting the presence of the neoplastic cell retarding polypeptides.Type: GrantFiled: August 15, 1985Date of Patent: February 21, 1989Assignee: Oncogen, Inc.Inventors: Mohammed Shoyab, Hans Marquardt, George J. Todaro
-
Patent number: 4804626Abstract: A highly sensitive and specific monoclonal-immuno-radiometric assay (M-IRMA) for hCG, using monoclonal antibodies (Mabs) directed against a 37-amino acid synthetic polypeptide analogous to the carboxyl terminus (CTP) of beta-hCG. Accordingly, in one embodiment, a method is described for the determination of human chorionic gonadotrThe present invention was made utilizing funds of the United States Government. The U.S. government is therefore granted a royalty-free, non-exclusive, world wide, paid-up license in this invention.Type: GrantFiled: October 22, 1986Date of Patent: February 14, 1989Assignee: The General Hospital CorporationInventors: Dominique Bellet, Jack R. Wands, Mehmet Ozturk
-
Patent number: 4795715Abstract: Derivatives of propranolol which have the following structure: ##STR1## where R is X--(CH.sub.2).sub.n --O, X is NH.sub.2 or COOH, n is 1,2,3,4, or 5, provided that when n is 1, X must be COOH, and R is attached in the 4',5',6',7' or 8' position. The compounds are useful in immunoassay applications to (1) conjugate to a protein carrier in order to prepare antibodies to propranolol and (2) to conjugate to a tracer moiety such as a radiolabeled ligand, an enzyme, an enzyme substrate or a fluorescent dye.Type: GrantFiled: October 3, 1986Date of Patent: January 3, 1989Assignee: Drug Science FoundationInventors: Thomas D. Eller, Daniel R. Knapp
-
Patent number: 4795702Abstract: Method for assay of fragments produced by the reaction between the enzyme immunoglobulin A protease and its substrate immunoglobulin A, sub-class 1. IgA1, IgAP and also bacteria which secrete IgAP may be detected. The assay is especially useful in the detection of Neisseria gonorrhea and in the diagnosis of gonorrhea.Type: GrantFiled: February 5, 1986Date of Patent: January 3, 1989Assignee: Immunogon AssociatesInventor: Milan S. Blake
-
Patent number: 4794076Abstract: Methods and kits for performing a ligand/anti-ligand assay are described. The ligand/anti-ligand assay comprises: (1) simultaneously carrying out the extraction of a ligand from a sample of cells or cells and reaction of the ligand with at least two anti-ligands therefor to form a detectable reaction product, and (2) detecting the reaction product.Type: GrantFiled: September 23, 1985Date of Patent: December 27, 1988Assignee: VXR, Inc.Inventors: Henry W. Founds, Jr., Roger N. Piasio
-
Patent number: 4784958Abstract: A simple method for preparing highly radioactive 1,4-dihydropyridine and 1,4-dihydroquinoline derivatives labelled with .sup.125 I enables a specific radioactivity of approx. 2200 to 8800 Ci/m Mole to be achieved. In this way high sensitivity in medicament screening with the aid of radioreceptor assays and in determining plasma levels of 1,4-dihydropyridines, 1,4-dihydroquinolines and other substances that inter-react with receptors for 1,4-dihydropyridines and 1,4-dihydroquinolines is achieved, with the result that a substantially shorter exposure time in the auto-radiographic identification of the receptors for these substances is required. For this purpose an amino derivative of a 1,4-dihydropyridine or 1,4-dihydroquinoline is reacted with an acylating reagent radiactively labelled with .sup.125 I (2200-4400 Ci/mMole), and the .sup.Type: GrantFiled: November 19, 1984Date of Patent: November 15, 1988Inventor: Hartmut Glossman
-
Patent number: 4775745Abstract: This invention relates to a diazonium compound of the formula: ##STR1## wherein Z is selected from the group consisting of biotin, an antigen, an antibody, a photoreactive group, a fluorescent group and heavy metal-containing compounds;X is an alkylene group containing up to 18 carbon atoms in the principle chain and a total of up to 24 carbon atoms or a substituted alkylene group containing up to 18 carbon atoms in the principle chain with substituents selected from the group consisting of solubility-enhancing groups and cleavable --S--S-- containing moieties;Ar is an unsubstituted or substituted aryl or heteroaryl; andY is an anion and n is an integer from 1-3.Such compounds are useful as components for nucleic acid probes.Type: GrantFiled: December 8, 1986Date of Patent: October 4, 1988Assignee: National Distillers and Chemical CorporationInventors: John P. Ford, Bernard F. Erlanger, C. William Blewett
-
Patent number: 4775638Abstract: A method for radiolabeling protein such as antibody which is performed in a single reaction vessel is described. A sealed reaction vessel having a port for addition and withdrawal of reagents preferably by syringe is used. Reagents for coupling radioisotope to the protein are added to the vessel. For radioiodination procedures, vessels can be pre-coated with the iodine coupling agent iodgen. The protein and the radioisotope are then added to the vessel and the radiolabel reaction allowed to proceed. After the reaction is complete, a resin is added to the vessel to adsorb the uncoupled radioisotope. The entire reaction mixture is then withdrawn from the vessel and the resin is separated from the protein preferably by sterile filtration.Type: GrantFiled: May 8, 1985Date of Patent: October 4, 1988Assignee: Centocor, Inc.Inventor: Hidde J. Haisma
-
Patent number: 4772548Abstract: A method of forming a therapeutic or diagnostic agent labeled with a radioactive metal ion, which comprises: contacting an unlabeled therapeutic or diagnostic agent, consisting of a substantially non-metal chelating portion and a chelating portion capable of chelating with the radioactive metal ion, with an ion transfer material having the radioactive metal ion bound thereto and having a binding affinity for the radioactive metal less than the binding affinity of the chelating portion for the radioactive metal ion, wherein prior to contacting the chelating portion is unchelated or is chelated with a second metal having a binding affinity with the chelating portion less than the binding affinity of the radioactive metal ion, whereby a radiolabeled therapeutic or diagnostic agent is formed by the contacting, and separating the radiolabeled therapeutic or diagnostic agent from the ion transfer material, is disclosed along with various components and kits useful in practicing this method and several variations thType: GrantFiled: January 23, 1987Date of Patent: September 20, 1988Assignee: Enzo Biochem, Inc.Inventor: Jannis G. Stavrianpoulos